Maria Lyme healing

08/11/2025

https://www.facebook.com/profile.php?id=61583132205540

Radi bychom vsem postizenym lidem poradili s dobre dokumentovanou lecbou,pani doktorka profesorka svymi znalostni,zkusenostmi s kombinaci s alternativni lecbou vylecila stav pacientu behem nekolika let o 50%...

06/11/2025

All people who needs our help please contact Peter over here
https://www.facebook.com/countpetr.vanicek/

06/11/2025

Mycoplasma and babesia grade 4 in a women who got a tick bite in 2013 and is very sick ever since with chronic pain and fatigue,headaches,anxienty,panic attacks and depression

06/11/2025

30/10/2025

COVID prevention and treatment - Dr. Richard Horowitz:

I just received a message from the administrator of a nursing home who was interested in my COVID protocol, using ivermectin and high dose glutathione, along with scientific references, so she could protect her vulnerable population. We sent it to her, and it appears not too soon. The latest figures are that there is a death every 33 seconds in the US from COVID.

Here again is the prevention and treatment protocol we have been recommending. I posted several days ago almost 100 scientific references backing up the protocol for the RCT at UCI.

Regarding dosage, it varies based on whether you are looking for prevention or treatment.

Prevention:
- NAC 600 mg BID,
- Alpha lipoic acid 600 mg once to twice a day,
- glutathione 250-500 mg BID (I am taking 750 mg BID),
- curcumin 500-1000 mg twice a day,
- sulforaphane glucosinolate 100 mg twice a day (broccoli seed extract),
- zinc 40-50 mg/day,
- Vit C 1 gram TID,
- 3,6 Beta glucan 500 mg per day,
- Vit D 5000 IU/day,
- melatonin 1 mg at bed.

For active infection:
- NAC is doubled to two twice a day, and
- glutathione
dosing goes up to 2000 mg 2-3 x per day,
- with an increase in Vit C to 2000 mg TID.

The rest of the supplements can remain the same.

Along with the nutraceuticals, we have been using IVERMECTIN (0.2 mg/kg) once a day for 14 days based on multiple peer-reviewed articles on its efficacy for COVID.

The above protocol has worked well so far for almost 50 active patients.

Not one of my chronic Lyme patients has ended up in a hospital to date if they used this protocol.

30/10/2025

Dr. Richard Horowitz:

"This is the second article in a week on Bartonella.
I have the same comments: there is no discussion of Bart being a biofilm/persister bacteria, and requires long-term follow-up to evaluate relapses.

Not one of our chronically ill patients will respond to a single drug regimen like zithromax.
The Johns Hopkins research on the topic is clear...
"Abstract
Background
Bartonella henselae is a Gram-negative bacterium transmitted to humans by a scratch from cat in the presence of ectoparasites. Humans infected with B. henselae can result in various clinical diseases including local lymphadenopathy and more serious systemic disease such as persistent bacteremia and endocarditis.

The current treatment of persistent B. henselae infections is not very effective and remains a challenge. To find more effective treatments for persistent and biofilm Bartonella infections, in this study, we evaluated a panel of drugs and drug combinations based on the current treatment and also promising hits identified from a recent drug screen against stationary phase and biofilm recovered cells of B. henselae.

Results
We evaluated 14 antibiotics and 25 antibiotic combinations for activity against stationary phase B. henselae (all antibiotics were at 5 μg/ml) and found that ciprofloxacin, gentamicin, and nitrofurantoin were the most active agents, while clofazimine and miconazole had poor activity.

Drug combinations:
- azithromycin/ciprofloxacin,
- azithromycin/methylene blue,
- rifampin/ciprofloxacin, and
- rifampin/methylene blue

could rapidly kill stationary phase B. henselae with no detectable CFU after 1-day exposure.

Methylene blue and rifampin were the most active agents against the biofilm B. henselae after 6 days of drug exposure.

Antibiotic combinations:
- azithromycin/ciprofloxacin,
- azithromycin/methylene blue,
- rifampin/ciprofloxacin,
- rifampin/methylene blue

completely eradicated the biofilm B. henselae after treatment for 6 days.

Conclusions
These findings may facilitate development of more effective treatment of persistent Bartonella infections in the future.

Keywords: Bartonella henselae, Stationary phase, Biofilm, Antimicrobial activity, Drug combination"

Zheng X, Ma X, Li T, Shi W, Zhang Y. Effect of different drugs and drug combinations on killing stationary phase and biofilms recovered cells of Bartonella henselae in vitro. BMC Microbiol. 2020 Apr 10;20(1):87. doi: 10.1186/s12866-020-01777-9. PMID: 32276590; PMCID: PMC7149919. -
Dr Richard Horowitz

30/10/2025

Dr Richard Horowitz:

Four months after getting a Lyme infection, Borrelia has undoubtedly gone into biofilm/persister forms. So although IV Rocephin and doxycycline were used effectively in the initial therapeutics, once these antibiotics are stopped, it is likely the patient will relapse. Neuroborreliosis can involve biofilms.

Di Domenico EG, Cavallo I, Bordignon V, D'Agosto G, Pontone M, Trento E, Gallo MT, Prignano G, Pimpinelli F, Toma L, Ensoli F. The Emerging Role of Microbial Biofilm in Lyme Neuroborreliosis. Front Neurol. 2018 Dec 3;9:1048. doi: 10.3389/fneur.2018.01048. PMID: 30559713; PMCID: PMC6287027.

There was no mention of biofilms and persisters in this article, only mentioning IDSA guidelines, that have no answers for chronic Lyme disease. This is a continuous issue with the journal Cureus. None of the editors feel it is important to discuss the large body of published medical literature on this subject, and without a longer-term follow-up, we can't know the results. What I do know: I have had patients relapse after 12 continuous months of IV Rocephin (not from me, from other doctors who were treating) who then came to me, and went into long-term remission after dapsone combination therapy.

28/10/2025

https://www.cureus.com/articles/415305-disseminated-bartonella-henselae-infection-in-a-patient-with-relapsedrefractory-multiple-myeloma-following-autologous-stem-cell-transplantation #!/

Bartonella henselae is the causative agent of cat scratch disease (CSD), a zoonotic illness primarily transmitted to humans through scratches or bites from cats and, less commonly, by cat fleas or lice. While the most common presentation is self-limited regional lymphadenopathy in immunocompetent in...

28/10/2025

Dr. Richard Horowitz:

"This is the second article in a week on Bartonella.
I have the same comments: there is no discussion of Bart being a biofilm/persister bacteria, and requires long-term follow-up to evaluate relapses. Not one of our chronically ill patients will respond to a single drug regimen like zithromax.
The Johns Hopkins research on the topic is clear...
"Abstract
Background
Bartonella henselae is a Gram-negative bacterium transmitted to humans by a scratch from cat in the presence of ectoparasites. Humans infected with B. henselae can result in various clinical diseases including local lymphadenopathy and more serious systemic disease such as persistent bacteremia and endocarditis. The current treatment of persistent B. henselae infections is not very effective and remains a challenge. To find more effective treatments for persistent and biofilm Bartonella infections, in this study, we evaluated a panel of drugs and drug combinations based on the current treatment and also promising hits identified from a recent drug screen against stationary phase and biofilm recovered cells of B. henselae.

Results
We evaluated 14 antibiotics and 25 antibiotic combinations for activity against stationary phase B. henselae (all antibiotics were at 5 μg/ml) and found that ciprofloxacin, gentamicin, and nitrofurantoin were the most active agents, while clofazimine and miconazole had poor activity. Drug combinations azithromycin/ciprofloxacin, azithromycin/methylene blue, rifampin/ciprofloxacin, and rifampin/methylene blue could rapidly kill stationary phase B. henselae with no detectable CFU after 1-day exposure. Methylene blue and rifampin were the most active agents against the biofilm B. henselae after 6 days of drug exposure. Antibiotic combinations (azithromycin/ciprofloxacin, azithromycin/methylene blue, rifampin/ciprofloxacin, rifampin/methylene blue) completely eradicated the biofilm B. henselae after treatment for 6 days.

Conclusions
These findings may facilitate development of more effective treatment of persistent Bartonella infections in the future.

Keywords: Bartonella henselae, Stationary phase, Biofilm, Antimicrobial activity, Drug combination"

Zheng X, Ma X, Li T, Shi W, Zhang Y. Effect of different drugs and drug combinations on killing stationary phase and biofilms recovered cells of Bartonella henselae in vitro. BMC Microbiol. 2020 Apr 10;20(1):87. doi: 10.1186/s12866-020-01777-9. PMID: 32276590; PMCID: PMC7149919. -
Dr Richard Horowitz

27/10/2025

21:01
Poslali jste
Dear members of the ConferinteMedicale.ro team,

Thank you for the honorable invitation to academic collaboration within the scientific and educational programs that you coordinate.

I gladly confirm my availability and interest to participate as a lecturer/session coordinator/moderator, in accordance with the EMC objectives and standards of the platform.

In particular, I would like to emphasize my particularly extensive expertise in the diagnosis, management and treatment of Lyme disease, as a Lyme Literate Medical Doctor (LLMD), integrated with clinical experience in neurosurgery and neurosciences.

Area of expertise:

1. Lyme disease and tick-borne co-infections:
- differential diagnosis,
- testing in case of suspected Lyme disease and associated co-infections,
- individualized and multidisciplinary management.

2. Neuroborreliosis and peripheral and central neurological manifestations:
- clinical evaluation,
- testing, imaging (DFM?, GIEMSA stains) and therapeutic management.

3. Relevant coinfections:
- Bartonella spp., Babesia spp., Anaplasma/Ehrlichia – impact on diagnosis, therapy and clinical outcome.

4. Systemic manifestations:
- musculoskeletal,
- cardiac (Lyme carditis),
- dermatological,
- ophthalmological,
- neuropsychiatric,
- systemic inflammation

5. Integrated interpretation of laboratory tests:
- standard serology,
- confirmatory tests,
- targeted PCR,
- Dark Field Microscopy, GIEMSA stain
- clinical-biological correlation.

6. Management of persistent (CHRONIC)/recurrent forms and post-treatment Lyme syndrome (PTLD), in accordance with current evidence and the principles of evidence-based medicine.

7. Development of clinical algorithms, effective treatment and monitoring protocols, as well as interdisciplinary clinical pathways.

8. Proposed areas and themes (Lyme – priority axis)

- Practical algorithm for the diagnosis of Lyme disease: from clinical suspicion to laboratory confirmation and therapeutic decision.

- Neuroborreliosis: diagnostic criteria, testing and imaging, therapeutic options and follow-up.

- Coinfections in Lyme disease: when to suspect them, how to test them and how they influence treatment.

- Lyme with cardiac involvement: screening, management and prevention of complications.

- Approach to the patient with persistent symptoms after treatment: differentiation between infectious activity, sequelae in recovery and comorbidities.

9. Guidelines and controversies: evidence-based alignment, individualized therapy, and interdisciplinary collaboration.

10. Complex case studies: differential diagnosis between Lyme, autoimmune spectrum disorders, neuropathies, spinal pathology, and dysautonomia.

11. Practitioner education: diagnostic pitfalls, correct test indication, patient risk/benefit communication, therapeutic approaches.

Preferred formats:
- Plenary conferences and multidisciplinary sessions.

- Practical masterclasses and case study workshops.

- EMC-accredited roundtables and webinars, with Q&A sessions focused on clinical decisions.

Availability 2026:
Flexible throughout the year, with priority for February–June and September–November.

I remain at your disposal for logistical, technical and academic details, as well as for the transmission of titles, abstracts and professional bios, in the requested format.

With thanks and consideration,

Doctor Tatiana Roșca
Chief Physician Neurosurgery
Lyme Literate Medical Doctor (LLMD)
Doctor of Medical Sciences